Honors Theses and Capstones

Production of Human Alpha-Galactosidase A in Arabidopsis thaliana

Katherine Lantz, University of New Hampshire


Current methods of mammalian tissue culture to manufacture human enzymes for use in Enzyme Replacement Therapy are expensive, time intensive, and prone to viral attack. In order to provide patients with Fabry Disease a safer and more affordable treatment, plants are being genetically engineered to produce the human enzyme alpha-galactosidase A. This enzyme can be harvested from transgenic plants to be used as an ERT drug to treat Fabry Disease.